Combined Use of a Novel Cardioplegic Formula With MPS® Versus Cardioplexol ® in Urgent Isolated CABG Using MiECC in Patients With Recent Acute Myocardial Infarction

University Hospital, Basel, Switzerland307 enrolled

Overview

The goal of this study is to compare the two cardioplegia solutions (blood cardioplegia by means of MPS ® vs. Cardioplexol ®) regarding perioperative outcome and with special attention to cardiac markers in patients with a recent heart attack.

Study Type

OBSERVATIONAL

Enrollment

307

Conditions

Heart Attack Cardioplegia Solution Adverse Reaction Coronary Artery Bypass Grafting (CABG)

Interventions

Myocardial protection system (MPS)OTHER

cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used

CardioplexolOTHER

cardioplegia solution

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who underwent a CABG using MPS® or Cardioplexol ® * Heart attack less than 7 days before surgery Exclusion Criteria: * use of other cardioplegia solution than Cardioplexol ® or MPS® * other inventions than CABG * explicit will of the patient that his data may not be used * denied general consent

Locations (1)

Cardiac Surgery Clinic University Hospital Basel

Basel, Switzerland

Outcomes

Primary Outcomes

myocardial damage

Analyse cardiac biomarkers as indicators for myocardial damage: high sensitive troponin (Ths-TrT, ng/mL), creatine kinase (CK, in ng/mL) and creatine kinase-MB isoenzyme (CK-MB, in ng/mL)

Time frame: patients with that received a coronary artery bypass grafting and that were treated (for approximately 15 days) at the University Hospital between February 2010 and January 2020 (data taken perioperative during hospital stay for CABG)

Secondary Outcomes

30 days Mortality

death after coronary artery bypass grafting

Time frame: 30 days after CABG

length of stay in the intensive care unit

duration of stay at intensive care unit

Time frame: perioperative during hospital stay for CABG (for approximately 15 days)

Number of participants with bleedings

bleeding complication after coronary artery bypass grafting

Time frame: perioperative during hospital stay for CABG (for approximately 15 days)

Number of participants with postoperative arrhythmia

rhythm disturbance after coronary artery bypass grafting

Time frame: perioperative during hospital stay for CABG (for approximately 15 days)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.